Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment

  • Luis F. Gonzalez-Cuyar
  • Joshua A. Sonnen
  • Kathleen S. Montine
  • C. Dirk Keene
  • Thomas J. Montine


Biomarkers are one type of laboratory testing being developed in response to the therapeutic imperative for diseases that cause cognitive impairment and dementia. The role of biomarkers is already transforming the organization and conduct of clinical trials, and if successful will likely contribute in the future to the medical management of patients with these diseases. Despite the obvious utility of practicality of blood- or urine-based biomarkers, so far results from these fluid compartments have not been reproducible. In contrast, substantial progress has been made in cerebrospinal fluid biomarkers. Here we review the stages of cerebrospinal fluid biomarker development for several common and unusual diseases that cause cognitive impairment and dementia, stressing the distinction between diagnostic and mechanistic biomarkers. Future applications will likely focus on diagnosis of latent or early-stage disease, assessment of disease progression, mechanism of injury, and response to experimental therapeutics.


Alzheimer’s disease Parkinson’s disease Vascular brain injury Biomarkers Cerebrospinal fluid Neurodegenerative disorders Mild cognitive impairment 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Montine TJ, Larson EB. Late-life dementias: does this unyielding global challenge require a broader view? Jama. 2009;302:2593–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Longstreth Jr WT, Sonnen JA, Koepsell TD, et al. Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord. 2009;23:291–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62:406–13.PubMedCrossRefGoogle Scholar
  4. 4.
    White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann N Y Acad Sci. 2002;977:9–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18:691–701.PubMedGoogle Scholar
  6. 6.
    Montine T, Sonnen J, Montine K, Crane P, Larson E. Adult changes in thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res. 2011, In pressGoogle Scholar
  7. 7.
    Dowling NM, Tomaszewski Farias S, Reed BR, et al. Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults. J Int Neuropsychol Soc. 2010: 1–13Google Scholar
  8. 8.
    Sonnen J, Santa Cruz K, Hemmy L, et al. Ecology of aging human brain. Arch Neurol. 2011, In pressGoogle Scholar
  9. 9.
    Lorenzi M, Donohue M, Paternico D, et al. Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild cognitive impairment. Neurobiol Aging. 2010;31:1443–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Kohannim O, Hua X, Hibar DP, et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging. 2010;31:1429–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Sonnen JA, Montine KS, Quinn JF, Breitner JC, Montine TJ. Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis. 2010;19:301–9.PubMedGoogle Scholar
  12. 12.
    Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer’s disease. Biomark Med. 2010;4:27–36.PubMedCrossRefGoogle Scholar
  13. 13.
    McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011Google Scholar
  14. 14.
    Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011Google Scholar
  15. 15.
    Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011Google Scholar
  16. 16.
    •• Trojanowski JQ, Vandeerstichele H, Korecka M, et al. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010, 6:230–8. Reviews progress in CSF biomarkers made in ADNI, a broadly collaborative study working to standardize application of selected CSF biomarkers. PubMedCrossRefGoogle Scholar
  17. 17.
    Weiner MW, Aisen PS, Jack Jr CR, et al. The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6:202–11 e7.PubMedCrossRefGoogle Scholar
  18. 18.
    Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging. 2011: epub ahead of printGoogle Scholar
  20. 20.
    • Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230–40. Reflects emerging consensus for some CSF biomarkers in PD. PubMedCrossRefGoogle Scholar
  21. 21.
    • Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011, 69:570–80. Reflects emerging consensus for some CSF biomarkers in PD. PubMedCrossRefGoogle Scholar
  22. 22.
    Yates D. New developments in CSF biomarkers for early detection and monitoring of Parkinson disease. Nat Rev Neurol. 2011;7:1.PubMedCrossRefGoogle Scholar
  23. 23.
    Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009;11:e22.PubMedCrossRefGoogle Scholar
  24. 24.
    Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem Biophys Res Commun. 2006;345:967–72.PubMedCrossRefGoogle Scholar
  25. 25.
    • Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010, 133:713–26. Reflects emerging consensus for some CSF biomarkers in PD. PubMedCrossRefGoogle Scholar
  26. 26.
    Maita C, Tsuji S, Yabe I, et al. Secretion of DJ-1 into the serum of patients with Parkinson’s disease. Neurosci Lett. 2008;431:86–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Devic I, Hwang H, Edgar JS, et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 2011, epub ahead of printGoogle Scholar
  28. 28.
    Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatr. 2010;81:1080–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid beta 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010;25:2682–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Brouns R, De Vil B, Cras P, et al. Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem. 2010;56:451–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Al-Tamimi M, Gardiner EE, Thom JY, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke. 2011;42:498–500.PubMedCrossRefGoogle Scholar
  33. 33.
    Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer’s disease. Exp Gerontol. 2010;45:75–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Chohan G, Pennington C, Mackenzie JM, et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatr. 2010;81:1243–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Satoh K, Tobiume M, Matsui Y, et al. Establishment of a standard 14-3-3 protein assay of cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease. Lab Investig. 2010;90:1637–44.PubMedCrossRefGoogle Scholar
  36. 36.
    van Harten AC, Kester MI, Visser PJ, et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med. 2011;49:353–66.PubMedCrossRefGoogle Scholar
  37. 37.
    Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827–35.PubMedCrossRefGoogle Scholar
  38. 38.
    Hu WT, Chen-Plotkin A, Grossman M, et al. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology. 2010;75:2079–86.PubMedCrossRefGoogle Scholar
  39. 39.
    Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med. 2005;38:698–710.PubMedCrossRefGoogle Scholar
  40. 40.
    Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer’s disease. J Neurosci Res. 2002;70:447–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Montine TJ, Peskind ER, Quinn JF, et al. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer’s disease as identified by biomarkers. Neuromolecular Med. 2011;13:37–43.PubMedCrossRefGoogle Scholar
  42. 42.
    Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001;21:4183–7.PubMedGoogle Scholar
  43. 43.
    Yao Y, Zhukareva V, Sung S, et al. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology. 2003;61:475–8.PubMedGoogle Scholar
  44. 44.
    Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology. 1999;52:562–5.PubMedGoogle Scholar
  45. 45.
    Pratico D, Clark CM, Lee VM, et al. Increased 8,12-iso-iPF2alpha-VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 2000;48:809–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Montine TJ, Kaye JA, Montine KS, et al. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 2001;125:510–2.PubMedGoogle Scholar
  47. 47.
    Pratico D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann Neurol. 2002;52:175–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2A isoprostane levels in Alzheimer’s and Parkinson’s disease. Neurodegener Dis. 2007;4:403–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Mufson EJ, Leurgans S. Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer’s disease. Neurodegener Dis. 2010;7:139–42.PubMedCrossRefGoogle Scholar
  51. 51.
    de Leon MJ, Mosconi L, Li J, et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol. 2007;254:1666–75.PubMedCrossRefGoogle Scholar
  52. 52.
    Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71:85–92.PubMedCrossRefGoogle Scholar
  53. 53.
    Quinn JF, Montine KS, Moore M, et al. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer’s disease. J Alzheimers Dis. 2004;6:93–7.PubMedGoogle Scholar
  54. 54.
    Wee Yong V. Inflammation in neurological disorders: a help or a hindrance? Neuroscientist. 2010;16:408–20.PubMedCrossRefGoogle Scholar
  55. 55.
    Lindberg C, Chromek M, Ahrengart L, et al. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer’s disease. Neurochem Int. 2005;46:551–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Popp J, Bacher M, Kolsch H, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res. 2009;43:749–53.PubMedCrossRefGoogle Scholar
  57. 57.
    Sun YX, Minthon L, Wallmark A, et al. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2003;16:136–44.PubMedCrossRefGoogle Scholar
  58. 58.
    Galimberti D, Schoonenboom N, Scheltens P, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006;63:538–43.PubMedCrossRefGoogle Scholar
  59. 59.
    Choi C, Jeong JH, Jang JS, et al. Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer’s disease by color-coded bead technology. J Clin Neurol. 2008;4:84–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Wang Y, Hancock AM, Bradner J, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am J Pathol. 2011;178:1509–16.PubMedCrossRefGoogle Scholar
  61. 61.
    Freund-Levi Y, Hjorth E, Lindberg C, et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study. Dement Geriatr Cogn Disord. 2009;27:481–90.PubMedCrossRefGoogle Scholar
  62. 62.
    Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology. 2007;68:1902–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61:668–72.PubMedCrossRefGoogle Scholar
  64. 64.
    Roberts RO, Geda YE, Knopman DS, et al. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement. 2009;5:398–405.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Luis F. Gonzalez-Cuyar
    • 1
  • Joshua A. Sonnen
    • 1
  • Kathleen S. Montine
    • 1
  • C. Dirk Keene
    • 1
  • Thomas J. Montine
    • 1
  1. 1.Department of PathologyUniversity of WashingtonSeattleUSA

Personalised recommendations